ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance
Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.
You may also be interested in...
Novartis Confident Cosentyx Can Keep Competition At Bay
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
AbbVie’s Skyrizi Tops Novartis’s Cosentyx In Psoriasis Contest
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance
Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.